Palonosetron for the treatment of chemotherapy-induced nausea and vomiting

Antiemetic efficacy and safety of a combination of palonosetron, aprepitant, and dexamethasone in patients with testicular germ cell tumor receiving 5-day cisplatin-based combination chemotherapy

(2014) Shota Hamada et al.   SUPPORTIVE CARE IN CANCER

Efficacy and safety of palonosetron for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis of randomized controlled trials

(2014) Marko Popovic et al.   SUPPORTIVE CARE IN CANCER

Olanzapine for chemotherapy-induced nausea and vomiting: a systematic review

(2014) Christopher M. Hocking et al.   SUPPORTIVE CARE IN CANCER

Management of Chemotherapy-Induced Nausea and Vomiting

(2013) Rudolph M. Navari   DRUGS

Olanzapine for the prevention and treatment of chronic nausea and chemotherapy-induced nausea and vomiting

(2013) Rudolph M. Navari   EUROPEAN JOURNAL OF PHARMACOLOGY

The current status of the use of palonosetron

(2013) Rudolph Navari   EXPERT OPINION ON PHARMACOTHERAPY

Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Highly or Moderately Emetogenic Chemotherapy: A Randomized, Double-Blind, Placebo-Controlled Study

(2013) Naomi Mizukami et al.   JOURNAL OF PAIN AND SYMPTOM MANAGEMENT

Efficacy of oral palonosetron compared to intravenous palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: a phase 3 trial

(2013) Ralph Boccia et al.   SUPPORTIVE CARE IN CANCER

Pooled analysis of phase III clinical studies of palonosetron versus ondansetron, dolasetron, and granisetron in the prevention of chemotherapy-induced nausea and vomiting (CINV)

(2013) Lee Schwartzberg et al.   SUPPORTIVE CARE IN CANCER

Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update

(2011) Ethan Basch et al.   JOURNAL OF CLINICAL ONCOLOGY

A phase III open-label study to assess safety and efficacy of palonosetron for preventing chemotherapy-induced nausea and vomiting (CINV) in repeated cycles of emetogenic chemotherapy

(2011) Kenjiro Aogi et al.   SUPPORTIVE CARE IN CANCER

Pneumatosis intestinalis in children with acute lymphoblastic leukemia and acute myeloid leukemia

(2011) Siyang Li et al.   SUPPORTIVE CARE IN CANCER

Double-blind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy

(2010) M. Aapro et al.   ANNALS OF ONCOLOGY

Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference

(2010) F. Roila et al.   ANNALS OF ONCOLOGY

Palonosetron to prevent nausea and vomiting in children undergoing BMT: efficacy and safety

(2010) M Ripaldi et al.   BONE MARROW TRANSPLANTATION

Palonosetron for the prevention of chemotherapy-induced nausea and vomiting in patients with cancer

(2010) Rudolph M Navari   Future Oncology

Efficacy and tolerability of transdermal granisetron for the control of chemotherapy-induced nausea and vomiting associated with moderately and highly emetogenic multi-day chemotherapy: a randomized, double-blind, phase III study

(2010) Ralph V. Boccia et al.   SUPPORTIVE CARE IN CANCER

Efficacy of palonosetron (PAL) compared to other serotonin inhibitors (5-HT3R) in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately or highly emetogenic (MoHE) treatment: systematic review and meta-analysis

(2010) Tobias Engel Ayer Botrel et al.   SUPPORTIVE CARE IN CANCER

Palonosetron and dexamethasone for prevention of nausea and vomiting in patients receiving high-dose chemotherapy with auto-SCT

(2009) M Musso et al.   BONE MARROW TRANSPLANTATION

Aprepitant

(2009) Monique P. Curran et al.   DRUGS

Palonosetron triggers 5-HT3 receptor internalization and causes prolonged inhibition of receptor function

(2009) Camilo Rojas et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Clinical research of Olanzapine for prevention of chemotherapy-induced nausea and vomiting

(2009) Lijun Tan et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial

(2009) Mitsue Saito et al.   LANCET ONCOLOGY

Palonosetron in Prevention of Nausea and Vomiting After Highly Emetogenic Chemotherapy Before Haematopoietic Stem Cell Transplantation—Single Center Experience

(2009) P. Rzepecki et al.   TRANSPLANTATION PROCEEDINGS